3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
17
Carboplatin
10
Paclitaxel
7
Trastuzumab
5
Nivolumab
5
Gemcitabine
5
Early Intervention, Educational
5
Cyclophosphamide
5
Cisplatin
5
fludarabine
4
cemiplimab
4
Psychiatric Rehabilitation
4
Fluorouracil
4
Docetaxel
4
Counseling
4
Albumin-Bound Paclitaxel
4
tisotumab vedotin
3
belinostat
3
Radiotherapy
3
Polymerase Chain Reaction
3
Methods
3
Magnetic Resonance Spectroscopy
3
Gene Expression Profiling
3
Fluorodeoxyglucose F18
3
Biopsy
3
zimberelimab
2
ulixertinib
2
pertuzumab
2
palbociclib
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
AZD9833
×
Gynecologic
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled